Annovis Bio, Inc. (ANVS): auditor change — Annovis Bio restates 2022 interim financials due to R&D expense misclassification; expects material weakness

Annovis Bio, Inc.

Material amounts of R&D expenses were misclassified as prepaid assets in Q1-Q3 2022 interim financials.
Previously issued unaudited financials for March 31, June 30, and September 30, 2022 should no longer be relied upon.
Company expects to report at least one material weakness in internal control over financial reporting.
Restatements will be included in the 2022 Form 10-K; cash position for each period is not expected to change.
Audit Committee and Board concluded restatement is appropriate after consulting with management and auditor WithumSmith+Brown.

item 4.02

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Annovis Bio, Inc. reported that prior financial statements should not be relied upon.

Action: non reliance

Exact text from the filing

ear ended December 31, 2022 the restated financial statements for each of the Non-Reliance Periods (“Restatements”). As a result, the unaudited financial statements for each of the Non-Reliance Periods should no longer be relied on. S imilarly, any previously issued or filed reports, press releases, earnings releases, and investor presentations or other communications describing

View on SEC.gov

Browse all auditor changes →

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-029078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.